Brendan Smith

“Maybe just one more, actually, on kind of the total revenue mix conversation, and there's been a few here so far, but I guess just kind of given the recent clinical progress and kind of upcoming progress on the partners, too, can you give us a sense of what that total revenue mix ultimately looks like over the next…”

“I actually wanted to maybe ask a little bit higher level question. just about some of the underlying assumptions of the growth of the overall full cytometry market.”

“I actually wanted to follow up on your commentary regarding the cross-selling there just a little bit more. Can you maybe expound a bit on really what ultimate success kind of looks like within that initiative?”

“I actually wanted to ask about the auto-injector part of the business a bit. I'm wondering what your expectations for new partnerships there look like and if we should expect maybe any overlap in the new enhance and hypercrime deals you've been announced this year with some of those auto-injectors.”

“First, actually, on the auto-injector business, can you maybe just remind us what the development path there is looking like and how we should think about economics and timing of that over the next couple of years? if you think that would be compatible with Hypercon or that would require something different with…”